Etanercept (Enbrel®) Prior Authorization Request Form

To be completed and signed by the prescriber. To be used <u>only</u> for prescriptions which are to be filled through the Department of Defense (DoD) TRICARE Mail Order Pharmacy (TMOP). Express Scripts is the TMOP contractor for DoD.

Your patient receives their prescription drug benefit from the Department of Defense (DoD). The DoD prescription drug benefit plan requires that we review certain requests for coverage with the prescribing physician. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage can be provided. Before giving the prescription to the patient, please make a copy of this form, complete the following questions and give the completed form, along with the prescription, to the patient. Please instruct the patient to send this completed form, along with the prescription, to Express Scripts for processing.

If Express-Scripts already has your patient's prescription and has requested that you complete this form, the completed form may be faxed to: (877) 895-1900 (toll-free) or (602) 586-3911 (commercial). A copy of this form and explanations of the underlying clinical rationale and criteria for approval are available at www.pec.ha.osd.mil/PA Criteria and forms.htm.

| Drug fo | r which Prior | Authorization is requested: Etanerce | pt (Enbrel®) | | |
|---------|---|---|-----------------|----------------|--|
| Step | Please complete patient and physician information (Please Print) | | | | |
| 1 | Patient Name: Physician Name: | | | | |
| | Address: | Address: | | | |
| | Member # | Phone #: | | | |
| | Wichibel # | | | | |
| Cton | | Secure Fax #: | | | |
| Step | Please complete the clinical assessment: | | | | |
| 2 | | ntinuation of therapy with etanercept? | | | |
| | | t is approved for 1 year. Drug benefit coverage is limited to a quantity no vials (3 cartons of 4 vials) per six weeks. | t □ Yes | □ No | |
| | If no, proceed | d to Question 2. | | | |
| | Will the patient be receiving adalimumab (Humira[®]), anakinra (Kindor infliximab (Remicade[®]) in combination with etanercept? | | | | |
| | | t coverage is not approved. d to Question 3. | ☐ Yes | □ No | |
| | 3. Is the patie | nt diagnosed with juvenile rheumatoid arthritis? | | | |
| | If yes, procee | ed to Question 4. | ☐ Yes | □ No | |
| | If no, proceed | d to Question 5. | | | |
| | | tient had an inadequate response to at least one disease- anti-rheumatic drug (DMARD)? | | | |
| | If yes, benefit | t is approved for 1 year. Drug benefit coverage is limited to a quantity no vials (3 cartons of 4 vials) per six weeks. | t □ Yes | □ No | |
| | If no, benefit | coverage is not approved. | | | |
| | | pt being prescribed for the treatment of moderately to tive rheumatoid arthritis OR the treatment of active psoriation | | | |
| | | t is approved for 1 year. Drug benefit coverage is limited to a quantity no vials (3 cartons of 4 vials) per six weeks. | t □ Yes | □ No | |
| | If no, benefit | coverage is not approved. | | | |
| Step 3 | Please sign a | nd date: | | | |
| | | Prescriber Signature | Date | _ | |
| | | · | Latest revision | on: April 2003 | |